Document Detail

Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: Results from a pilot phase 2 study.
MedLine Citation:
PMID:  20671417     Owner:  NLM     Status:  In-Data-Review    
OBJECTIVE: Current therapies for acromegaly are unsatisfactory for some patients. High-dose thiazolidinediones have been reported to reduce serum GH levels in animal models of acromegaly. The objective of the study was to evaluate the effect of increasing doses of rosiglitazone on serum GH and IGF-I concentrations in acromegalic patients.
DESIGN: Phase 2 clinical trial.
PATIENTS AND METHODS: Five consecutive patients with active and uncontrolled acromegaly under conventional medical therapies were treated with increasing doses of rosiglitazone [4 mg/day every month, starting from 8 up to 20 mg/day] added to previous medical therapies for acromegaly.
RESULTS: Mean serum IGF-I concentrations decreased from 547±91 to 265±126 μg/l (p<0,001) during rosiglitazone treatment: 4 patients had normal serum IGF-I concentrations, and a patient had lowered serum IGF-I values, although still abnormal, at the end of the study. On the contrary, serum GH concentrations did not significantly changed during rosiglitazone therapy as well as other pituitary hormones. No relevant side effects of rosiglitazone were observed during the study period. Quantitative real time PCR and Western blotting showed that rosiglitazone lowered GH-dependent hepatic generation of IGF-I in HepG2 cell line.
CONCLUSIONS: Rosiglitazone reduces serum IGF-I concentrations in patients with uncontrolled acromegaly under conventional medical therapies, likely acting on the GH-dependent hepatic synthesis of IGF-I. Large studies are necessary to confirm the role of rosiglitazone as an adjunctive therapy for uncontrolled acromegalic patients under conventional medical therapies.
F Bogazzi; G Rossi; M Lombardi; F Raggi; C Urbani; C Sardella; C Cosci; E Martino
Related Documents :
8950617 - Diagnosis of growth hormone deficiency in adults.
11085187 - Dysregulation of the hypothalamic-pituitary-adrenal axis in short children with and wit...
3396497 - Different effects of intermittent and continuous growth hormone (gh) administration on ...
10698597 - Management of puberty in growth hormone deficient children.
3536447 - Measurement of messenger ribonucleic acid for luteinizing hormone beta-subunit, alpha-s...
21880277 - Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the ...
Publication Detail:
Type:  Journal Article     Date:  2010-07-29
Journal Detail:
Title:  Journal of endocrinological investigation     Volume:  34     ISSN:  1720-8386     ISO Abbreviation:  J. Endocrinol. Invest.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-04-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7806594     Medline TA:  J Endocrinol Invest     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  e43-51     Citation Subset:  IM    
Department of Endocrinology and Metabolism, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Resistin level is positively correlated with thrombotic complications in Southern Chinese metabolic ...
Next Document:  Vitamin D status may contribute to serum insulin-like growth factor I concentrations in healthy subj...